Theravance Biopharma Q3 2024: YUPELRI sales record $62.2M (+7%); net loss widens; board forms strategic review

Theravance Biopharma, Inc.

2024-Q3 EPS reported -$0.84 revenue$45,627,000

Total revenue $16.9M (Viatris collab); implied YUPELRI net sales $62.2M all-time high (7% YoY, 14% QoQ).
Net loss $12.7M vs $9.0M YoY; non-GAAP net loss from operations $2.9M vs $0.7M.
TRELEGY milestone: Q4 sales ~$260M needed for $25M payment, ~$610M for $50M; YTD sales $2.6B.
Board forms Strategic Review Committee to assess alternatives to unlock shareholder value.
CYPRESS (ampreloxetine) open-label enrollment on track for mid-2025 completion; data ~6 months later.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.